8-K: BD Reports Strong Q1 FY26, Completes Biosciences Spin-Off

Becton, Dickinson and Company announced stronger-than-expected first-quarter fiscal 2026 financial results and expects to complete the combination of its Biosciences and Diagnostic Solutions business with Waters Corporation today.

Summary

• Q1 FY26 revenue reached $5.252 billion, marking a 1.6% increase as reported and 0.4% on a foreign currency neutral (FXN) basis.
• New BD revenue, excluding the Life Sciences segment, increased 2.5% FXN.
• GAAP diluted earnings per share (EPS) was $1.34, a 28.8% increase from $1.04 in Q1 FY25.
• Adjusted diluted EPS was $2.91, representing a 15.2% decrease from $3.43 in Q1 FY25.
• The combination of BD's Biosciences and Diagnostic Solutions business with Waters Corporation is expected to close today, February 9, 2026.
• The company affirmed its full year fiscal 2026 revenue growth guidance for New BD (low single-digit plus GAAP, low single-digit FXN).
• Adjusted Diluted EPS guidance for New BD for FY26 is set between $12.35 and $12.65.
• Effective October 1, 2025, the company reorganized its organizational units into five distinct, separately-managed segments.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively due to stronger-than-expected Q1 performance, significant GAAP EPS growth, and the strategic completion of the Biosciences and Diagnostic Solutions business combination, which is expected to drive long-term growth for 'New BD'.

Positives

• Delivered stronger-than-expected first-quarter performance, reflecting disciplined execution and broad-based growth across key end markets.
• Reported revenue increased 1.6% to $5.252 billion for Q1 FY26.
• New BD revenue (excluding Life Sciences) increased 2.5% on a foreign currency neutral (FXN) basis.
• GAAP diluted earnings per share increased significantly by 28.8% to $1.34.
• The expected completion of the combination of BD's Biosciences and Diagnostic Solutions business with Waters Corporation marks a significant strategic milestone, allowing a full pivot to 'New BD' and intensified focus on core growth areas.
• Announced a $110 million investment to support the U.S. pharmaceutical supply chain for biologic drugs, expanding BD Neopak Glass Prefillable Syringe production.
• Expanded partnership with Ypsomed to develop a 5.5 mL version of the BD Neopak XtraFlow Glass Prefillable Syringe for large-volume self-injection systems.
• Received FDA 510(k) clearance for the EnCor EnCompass Breast Biopsy and Tissue Removal System, slated for early 2026 market entry.
• Expanded the PureWick portfolio with the first-of-its-kind PureWick Portable Collection System for urinary incontinence.
• Expanded the BD Surgiphor Surgical Wound Irrigation System to Europe to enhance patient safety.
• Achieved full enrollment of the iliac artery patient cohort in the AGILITY study for the Revello Vascular Covered Stent.
• Connected Care segment revenue increased 5.5% reported and 4.7% FXN.
• BD Interventional segment revenue increased 5.8% reported and 5.1% FXN.
• BioPharma Systems segment revenue increased 2.7% reported and 1.0% FXN.

Negatives

• Adjusted diluted earnings per share decreased 15.2% to $2.91 (15.7% FXN) compared to the prior year.
• Life Sciences segment revenue decreased 8.3% reported and 10.5% FXN.
• International revenue decreased 2.8% on a foreign currency neutral (FXN) basis.
• Medical Essentials segment revenue decreased 0.6% on a foreign currency neutral (FXN) basis.
• Interest income significantly decreased from $23 million in Q1 FY25 to $4 million in Q1 FY26.
• Other operating expense, net, increased 75.9% from $28 million in Q1 FY25 to $50 million in Q1 FY26.
• Integration, restructuring and transaction expense increased 20.4% from $92 million in Q1 FY25 to $111 million in Q1 FY26.

Risks

• Macroeconomic conditions and their impact on operations and healthcare spending, including tariffs and import/export restrictions.
• Disruptions in global transportation networks or other aspects of the supply chain, affecting raw material sourcing.
• Inflationary pressures, currency and interest rate fluctuations, and increased borrowing costs.
• Conditions in international markets, including geopolitical developments in Ukraine, the Middle East, and Asia.
• Competitive factors, such as changing customer preferences, new products, and emerging technologies like artificial intelligence (AI).
• Changes in research and development efforts or investment by pharmaceutical companies.
• Changes in reimbursement practices, coverage policies, and third-party payer cost containment measures.
• Product efficacy or safety concerns and related regulatory actions, including non-compliance with requirements for products like BD Alaris System, infusion sets, BD Vacutainer, and BD Pyxis.
• Product liability or other claims and potential damage to reputation.
• Changes to legislation or regulations impacting healthcare systems, medical practices, or customer preferences, such as China's volume-based procurement.
• Policy and regulatory changes implemented by the U.S. government, including funding cuts or changes in agency policy positions.
• New or changing laws and regulations impacting the business, including tax laws, environmental laws (sustainability, climate change), cybersecurity, AI, or privacy laws.
• Adverse impact of past, current, or future information and technology system disruptions, breaches, or breakdowns, including cyberattacks.
• Adverse impact related to the development, deployment, and use of AI in products and business operations.
• Labor disruptions.
• Suppliers' ability to provide necessary products and BD's ability to maintain favorable supplier arrangements.
• Increases in raw material, component, labor, duties, freight, energy, and other production costs.
• Adverse changes in regional, national, or foreign economic conditions, including access to credit markets.
• Risks relating to overall indebtedness.
• The possible impact of natural disasters and public health crises on business and the global healthcare system.
• Interruptions in manufacturing or sterilization processes, including restrictions on the use of ethylene oxide.
• Pricing and market pressures.
• Difficulties inherent in product development, delays in product introductions, and uncertainty of market acceptance of new products.
• The overall timing of the replacement or remediation of the BD Alaris Infusion System and its return to market in the U.S.
• Ability to achieve projected level or mix of product sales.
• Ability to successfully integrate any businesses acquired.
• Uncertainties of litigation, investigations, regulatory actions, subpoenas, settlements, fines, penalties, and/or other sanctions.
• The issuance of new or revised accounting standards.
• Risks associated with the proposed combination of BD's Biosciences and Diagnostic Solutions business with Waters Corporation, including the anticipated benefits and expected timing of completion.

Future Outlook

For the full fiscal year 2026, Becton, Dickinson and Company (New BD) affirms its GAAP revenue growth guidance of low single-digit plus and foreign currency neutral (FXN) revenue growth guidance of low single-digit. The company also provides adjusted diluted EPS guidance for New BD in the range of $12.35 to $12.65, reflecting adjustments for corporate overhead migrating to Waters Corp., TSA income, and the expected benefit from the use of proceeds from the separation.

Management Comments

• "We delivered stronger-than-expected first-quarter performance which reflects our disciplined execution, including accelerated commercial initiatives and broad-based growth across key end markets." Tom Polen, chairman, CEO and president of BD.
• "Today, we expect to complete the combination of BD's Biosciences and Diagnostic Solutions business with Waters Corporation. With this significant milestone in our strategy to drive shareholder value, we fully pivot to New BD and the next chapter of the company's growth—intensifying our focus on elevating commercial capabilities, advancing industry-leading innovation, and applying BD Excellence to drive productivity and gross margin expansion." Tom Polen.
• "Our Q1 results have positioned us well to achieve our fiscal 2026 guidance while creating a foundation for long-term revenue and earnings growth." Tom Polen.

Industry Context

StockSavvy.ai notes that Becton, Dickinson and Company's strategic pivot to 'New BD' by combining its Biosciences and Diagnostic Solutions business with Waters Corporation reflects a broader trend in the medical technology industry towards specialization and optimizing core portfolios. The company's investments in prefillable syringes for biologics and GLP-1 drugs align with the rapidly growing demand in the biopharma sector. Furthermore, the focus on connected care, point-of-care diagnostics, and advanced interventional systems demonstrates a commitment to innovation in high-growth areas of healthcare, addressing evolving patient needs and hospital efficiencies.

Comparison to Industry Standards

• The filing does not provide specific comparative financial metrics against direct competitors or industry benchmarks.
• StockSavvy.ai observes that while BD highlights its position as a 'leading global medical technology company,' a detailed assessment against peers like Medtronic, Abbott Laboratories, or Danaher (which has a significant life sciences tools segment) would require external data.
• The strategic combination with Waters Corporation, a leader in analytical instruments and software, suggests a move to create a more focused and potentially more competitive entity in its respective markets, similar to how other large conglomerates have spun off or divested non-core assets to unlock shareholder value.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for enhanced long-term value through strategic focus on 'New BD' and affirmed FY26 guidance, but the adjusted EPS decline in Q1 may warrant scrutiny.
• Employees: The reorganization and strategic pivot may lead to shifts in roles or focus, particularly for those in the divested Biosciences and Diagnostic Solutions business.
• Customers: New product introductions (e.g., EnCor EnCompass, PureWick Portable, BD Surgiphor in Europe) and investments in the supply chain (Neopak) aim to improve product offerings and availability.
• Patients: Benefits from new and expanded medical technologies, such as improved breast biopsy, urinary incontinence management, and drug delivery systems.
• Creditors: Current and long-term debt obligations are noted, with some short-term debt changes, but no immediate adverse impact is indicated.

Next Steps

• Completion of the combination of BD's Biosciences and Diagnostic Solutions business with Waters Corporation today, February 9, 2026.
• Full pivot to 'New BD' with intensified focus on elevating commercial capabilities, advancing innovation, and driving productivity and gross margin expansion.
• Management will discuss its outlook and assumptions on its first fiscal quarter earnings call today, February 9, 2026.
• The EnCor EnCompass Breast Biopsy and Tissue Removal System is slated to be in the market in early 2026.
• Continued execution to achieve fiscal 2026 guidance and create a foundation for long-term revenue and earnings growth.

Key Dates

Recommendation

While Becton, Dickinson and Company reported stronger-than-expected Q1 FY26 performance and a significant strategic milestone with the Biosciences and Diagnostic Solutions business combination, the decline in adjusted diluted EPS and negative FXN growth in the Life Sciences segment warrant a cautious approach. The affirmation of FY26 guidance for 'New BD' provides some stability, but investors should monitor the integration of the new structure and the execution of the strategic pivot to ensure sustained long-term growth and margin expansion. The stock is likely to be in a transitional phase, justifying a 'hold' until clearer trends emerge post-restructuring.

Keywords

Medical Technology, Healthcare, Financial Results, Earnings, Q1 2026, BDX, Becton Dickinson, Biosciences, Diagnostic Solutions, Waters Corporation, Spin-off, Divestiture, Medical Devices, Pharmaceutical Systems, Prefillable Syringes, Breast Biopsy, Urinary Incontinence, Surgical Wound Irrigation, Peripheral Artery Disease, Connected Care, Medication Management, Advanced Patient Monitoring, Medical Essentials, Interventional, Life Sciences